Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05982886 · ClinicalTrials.gov registry record
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,093
- Enrollment target
NCT05982886: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05982886 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,093 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05982886 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,093 participants
- Enrollment target
Study Summary
This was a retrospective observational study of patients with advanced breast cancer (BC). This non-interventional study was conducted using discrete structured data and medical record abstraction, if needed, from patients treated at Texas Oncology, the designated research organization and a community oncology practice. The first date of a new diagnosis of advanced BC (de novo or progressed to advanced BC) defined the study index date. To allow for an adequate potential duration of follow-up (retrospectively observed) after the index date over which PIK3CA testing and treatment patterns was observed, a minimum follow-up opportunity of 6 months after the diagnosis of advanced BC at the time of data pull and/or abstraction was required.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,093 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2021-04-01 |
What the finished NCT05982886 record still lists
NCT05982886 is an observational study that tracks outcomes without assigning an intervention. Its 1,093 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05982886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05982886 about?
NCT05982886 is a clinical study titled "Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer". This was a retrospective observational study of patients with advanced breast cancer (BC). This non-interventional study was conducted using discrete structured data and medical record abstraction, if needed, from patients treated at Texas Oncology, the designated research organization and a communi...
What is the current status of trial NCT05982886?
This trial is currently completed. The enrollment target is 1,093 participants. The study started on 2021-01-15. Estimated completion is 2021-04-01.
Who is sponsoring clinical trial NCT05982886?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06585241 · 1,094 participants · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI